Tirz GLP-2 (10Mg)
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a novel investigational peptide that acts as a dual agonist of GIP and GLP-1 receptors, enhancing insulin secretion and improving glycemic control while reducing appetite.
Usage:
Primarily studied in the treatment of Type 2 diabetes and obesity. Research also explores its cardiovascular and metabolic benefits.
Mechanism of Action:
Activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors to regulate blood sugar and appetite.
Benefits:
- Improved insulin sensitivity
- Appetite suppression
- Significant weight loss
- Better glycemic control
Side Effects:
- Nausea
- Vomiting
- Constipation
- Fatigue (in early dosing phase)
Suggested Dosage:
Not specified
Half-life: 5 days
Delivery: Subcutaneous injection